Trastuzumab

TERMINATED · PHASE3 · Breast Cancer, Metastasis, Sur-expressing Her2-neu

Lack of enrollment

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.